分化型甲状腺癌术后131I清甲疗效相关影响因素分析

目的:探讨分化型甲状腺癌术后131I清甲疗效相关影响因素。方法:回顾性分析分化型甲状腺癌术后131I清甲治疗患者128例临床资料，总结包括年龄、性别、病理分型、手术切除方式、肿瘤转移、肿瘤转移部位、血清促甲状腺激素（TSH）水平及131I治疗时间等临床特征对疗效的影响。结果:对不同性别、年龄、病理分型及肿瘤转移有无进行分组比较，分化型甲状腺癌患者术后131I治疗临床疗效差异无统计学意义（P＞0.05）；而行甲状腺全切、肿瘤颈部淋巴结转移、血清TSH水平20~40mIU/L及131I治疗时间≤6个月组分化型甲状腺癌患者术后131I清甲临床疗效显著优于其他分组，差异有统计学意义（P＜0.05）；手术切除方式、血清TSH水平及131I治疗时间是影响分化型甲状腺癌术后131I治疗效果独立因素。结论:分化型甲状腺癌术后131I清甲疗效与手术切除方式、血清TSH水平及131I治疗时间具有相关性。

Influencing factors of therapeutic effects of differentiated thyroid carcinoma treated by 131I for thyroid ablation

Objective:To investigate influencing factors of therapeutic effects of differentiated thyroid carcinoma treated by 131I for thyroid ablation.Methods:The clinical data of 128 patients with differentiated thyroid carcinoma treated by operative section and 131I therapy for thyroid ablation after operation were retrospectively analyzed to summarize the influence of clinical characteristic on therapeutic effects of differentiated thyroid carcinoma treated by 131I including age,gender,pathological type,methods of operative section,carcinoma metastasis，location of carcinoma metastasis,levels of serum TSH and treatment time of 131I.Results:There was no significant difference in therapeutic effects of differentiated thyroid carcinoma treated by using 131I of different group by age,gender,pathological type and carcinoma metastasis（P＞0.05）.The therapeutic effects of differentiated thyroid carcinoma treated by 131I for thyroid ablation of group with total thyroid section,carcinoma metastasis of neck lymph node,levels of serum TSH for 20~40mIU/L and treatment time of 131I for ≤6 months was significant better than other group（P＜0.05）.The independent influencing factors on therapeutic effects of differentiated thyroid carcinoma treated by using 131I included methods of operative section,levels of serum TSH and treatment time of 131I.Conclusion:The factors including methods of operative section,levels of serum TSH and treatment time of 131I could influence therapeutic effects of differentiated thyroid carcinoma treated by131I.